Chugai Pharmaceutical Co's total inventories for the quarter that ended in Mar. 2026 was $1,817 Mil. Chugai Pharmaceutical Co's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was $1,796 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Chugai Pharmaceutical Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was $1.73.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Chugai Pharmaceutical Co's Days Inventory for the
three
months ended in Mar. 2026 was 280.30.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Chugai Pharmaceutical Co's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.33.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Chugai Pharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.89.
Chugai Pharmaceutical Co (OTCPK:CHGCY) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Chugai Pharmaceutical Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Chugai Pharmaceutical Co's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Chugai Pharmaceutical Co Total Inventories Related Terms
Chugai Pharmaceutical Co Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chugai Pharmaceutical Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Chugai Pharmaceutical Co (CHGCY) has a Total Inventories of $1,817 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Chugai Pharmaceutical Co and its competitors.
Is Chugai Pharmaceutical Co's Total Inventories too high?
Chugai Pharmaceutical Co's current Total Inventories is $1,817 Mil. Overall, Chugai Pharmaceutical Co has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chugai Pharmaceutical Co's Total Inventories compare to LLY and JNJ?
Chugai Pharmaceutical Co's Total Inventories of $1,817 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Chugai Pharmaceutical Co and its competitors. Chugai Pharmaceutical Co's current Total Inventories is $1,817 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chugai Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co (CHGCY) is currently considered Fairly Valued. The stock's GF Value™ is $24.28, compared to a current price of $22.99 — trading 5.3% below its estimated fair value. The current Total Inventories is $1,817 Mil. Chugai Pharmaceutical Co's overall GF Score™ is 92/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Chugai Pharmaceutical Co (CHGCY), the current Total Inventories is $1,817 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chugai Pharmaceutical Co (CHGCY) Overvalued in 2026?
Based on GuruFocus' analysis, Chugai Pharmaceutical Co stock appears to be undervalued.
The current stock price of $22.99 is trading 5.3% below its estimated GF Value™ of $24.28.
GuruFocus considers Chugai Pharmaceutical Co to be Fairly Valued.
Key valuation signals for CHGCY:
Total Inventories: $1,817 Mil
GF Value™: $24.28 vs. price of $22.99 (5.3% below fair value)
No single metric tells the full story. See the CHGCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chugai Pharmaceutical is a Japanese drug developer and subsidiary of Roche Holding, which owns roughly 60% of the company. Founded in 1925, Chugai deals primarily in the Japanese market, where it generates roughly half of its revenue. It has been the leader in Japan's oncology market for the past decade, largely due to drugs licensed from its parent's portfolio. The company also develops its own innovative medicines. It is an industry leader in antibody technology with several flagship therapies, including Hemlibra (hemophilia), Actemra (rheumatoid arthritis, covid), Foundayo (oral obesity pill), and Nemluvio (atopic dermatitis, prurigo nodularis).
92GF Score
Get the complete analysis for CHGCY
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHGCY has been successfully added to your 
